Atlas Trials

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

Clinical trial NCT07272291 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07272291
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma (ESCC)
Start date
2025-12-25
Primary completion
2027-12-25
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.